|
PDIA3P expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.60939994453946E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.73560000038542E-07 |
| Normal-vs-Stage2 |
3.850100E-02 |
| Normal-vs-Stage3 |
1.44850020866727E-10 |
| Normal-vs-Stage4 |
4.02560000001273E-07 |
| Stage1-vs-Stage2 |
1.050160E-01 |
| Stage1-vs-Stage3 |
8.240700E-03 |
| Stage1-vs-Stage4 |
6.457600E-02 |
| Stage2-vs-Stage3 |
1.939600E-03 |
| Stage2-vs-Stage4 |
1.303760E-02 |
| Stage3-vs-Stage4 |
9.004800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.48709958078553E-10 |
| Normal-vs-AfricanAmerican |
4.799600E-02 |
| Normal-vs-Asian |
9.81559999946313E-08 |
| Caucasian-vs-AfricanAmerican |
5.386800E-01 |
| Caucasian-vs-Asian |
8.733000E-01 |
| AfricanAmerican-vs-Asian |
5.897800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.52753999999033E-05 |
| Normal-vs-Female |
2.74480005391098E-09 |
| Male-vs-Female |
2.723200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.88799999867717E-08 |
| Normal-vs-Age(41-60Yrs) |
1.22959999959704E-07 |
| Normal-vs-Age(61-80Yrs) |
3.02500000048944E-07 |
| Normal-vs-Age(81-100Yrs) |
1.072280E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.073600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.136800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.006800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.545200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.816600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.873600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.396505133755E-11 |
| Classical-VS-Follicular |
1.154000E-04 |
| Classical-VS-Other |
5.599800E-01 |
| Classical-VS-Normal |
9.36839994469807E-09 |
| Tall-VS-Follicular |
6.87228052242972E-14 |
| Tall-VS-Other |
8.679500E-02 |
| Tall-VS-Normal |
1.62436730732907E-12 |
| Follicular-VS-Other |
9.810400E-02 |
| Follicular-VS-Normal |
2.453000E-01 |
| Other-VS-Normal |
1.158350E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.20599999999349E-05 |
| Normal-vs-N1 |
7.21630533107032E-11 |
| N0-vs-N1 |
3.753200E-04 |
|
|
